Macquarie Group LTD Cerevel Therapeutics Holdings, Inc. Transaction History
Macquarie Group LTD
- $85.1 Billion
- Q2 2024
A detailed history of Macquarie Group LTD transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 4,285 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,285Holding current value
$0% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding CERE
# of Institutions
270Shares Held
155MCall Options Held
2.19MPut Options Held
3.92M-
Bain Capital Investors LLC Boston, MA65.7MShares$065.37% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$012.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.54MShares$04.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.15MShares$00.01% of portfolio
-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...